Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03393845 · ClinicalTrials.gov registry record · Phase 2
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
A Phase 2 study of Breast Cancer, sponsored by Nancy Chan, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 5
- Study locations
NCT03393845: Active Phase 2 study of Breast Cancer, sponsored by Nancy Chan, MD.
NCT03393845 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Nancy Chan, MD. The registered enrollment target is 47 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03393845, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Nancy Chan, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 5
- Study locations
Study Summary
Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Fulvestrant
Study Locations (5)
Michigan
- Michigan State University, Breslin Cancer Center - Lansing
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- New York University Clinical Cancer Center - New York
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-01-29 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03393845
The ClinicalTrials.gov registry entry for NCT03393845 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Nancy Chan, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03393845 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Michigan, Nebraska, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03393845 about?
NCT03393845 is a clinical study titled "Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients". Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
What is the current status of trial NCT03393845?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2018-01-29. Estimated completion is 2027-09-01.
What conditions does trial NCT03393845 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03393845?
The interventions under investigation include: Pembrolizumab (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT03393845?
This trial is sponsored by Nancy Chan, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03393845 being conducted?
This trial has 5 study locations across Michigan, Nebraska, New Jersey, New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.